Camps, C.; Jantus Lewintre, E.; Cabrera, A.; Blasco, A.; Sanmartin, E.; Gallach, S.; Caballero, C.... (2011). The identification of KRAS mutations at codon 12 in plasma DNA is not a prognostic factor in advanced non-small cell lung cancer patients. Lung Cancer. 72(3):365-369. https://doi.org/10.1016/j.lungcan.2010.09.005
Por favor, use este identificador para citar o enlazar este ítem: http://hdl.handle.net/10251/77414
Título:
|
The identification of KRAS mutations at codon 12 in plasma DNA is not a prognostic factor in advanced non-small cell lung cancer patients
|
Autor:
|
Camps, Carlos
Jantus Lewintre, Eloisa
Cabrera, Andrea
Blasco, Ana
Sanmartin, Elena
Gallach, Sandra
Caballero, Cristina
del Pozo, Nieves
Rosell, Rafael
Guijarro, Ricardo
Sirera Pérez, Rafael
|
Entidad UPV:
|
Universitat Politècnica de València. Escuela Técnica Superior de Ingeniería Agronómica y del Medio Natural - Escola Tècnica Superior d'Enginyeria Agronòmica i del Medi Natural
|
Fecha difusión:
|
|
Resumen:
|
Qualitative analysis of circulating DNA in the blood is a promising non-invasive diagnostic and prognostic tool. Our aim was to study the association between the presence of KRAS mutations at codon 12 and several clinical ...[+]
Qualitative analysis of circulating DNA in the blood is a promising non-invasive diagnostic and prognostic tool. Our aim was to study the association between the presence of KRAS mutations at codon 12 and several clinical variables in advanced non-small cell lung cancer (NSCLC) patients. Methods: We examined 308 stage IIIB and IV NSCLC patients who were treated with cisplatin and docetaxel. Blood samples were collected before chemotherapy, and circulating DNA was extracted from the plasma using commercial adsorption columns. The KRAS mutational status was determined by an RT-PCR method that is based on allelic discrimination. Results: The median age of the patients was 60 years [31-80], 84% were male, 98% had a performance status of 0-1 and 84% of the patients were in stage IV. The histological subtypes were as follows: 30% squamous cell carcinoma (SCC), 51% adenocarcinoma (ADC) and 19% others. Of the 277 response-evaluated patients, 1% achieved a complete response (CR), 26% achieved a partial response (PR), 34% had stable disease (SD) and 39% had progressive disease (PD). Additionally, 27 (8.8%) patients had KRAS mutations; 26 had a KRAS codon 12 TGT mutation, and 1 had a codon 12 GTT mutation. Plasmatic KRAS mutations were found in patients presenting SCC or ADC. Patients with KRAS mutations in plasma DNA had a median progression free survival (PFS) of 5.77 months [3.39-8.14], whereas for patients with wild-type (wt) KRAS, the PFS was 5.43 months [4.65-6.22] (p = 0.277). The median overall survival (OS) in KRAS-mutated patients was 9.07 months [4.43-13.70] vs 10.03 months [8.80-11.26] in wt patients (p = 0.514). Conclusions: In advanced NSCLC patients, there were no significant differences between patients with or without KRAS mutations in plasma-free DNA with respect to the baseline characteristics, response rates, PFS or OS. © 2010 Elsevier Ireland Ltd.
[-]
|
Palabras clave:
|
KRAS
,
Molecular markers
,
Non-small cell lung cancer (NSCLC)
,
Prognostic factors
,
Cisplatin
,
DNA
,
Docetaxel
,
Adult
,
Advanced cancer
,
Aged
,
Allele
,
Article
,
Blood sampling
,
Cancer chemotherapy
,
Cancer patient
,
Cancer staging
,
Cancer survival
,
Codon
,
Disease course
,
DNA extraction
,
Female
,
Gene mutation
,
Genetic association
,
Histopathology
,
Human
,
Lung adenocarcinoma
,
Lung non small cell cancer
,
Lung squamous cell carcinoma
,
Major clinical study
,
Male
,
Multiple cycle treatment
,
Oncogene K ras
,
Overall survival
,
Plasma
,
Priority journal
,
Prognosis
,
Progression free survival
,
Reverse transcription polymerase chain reaction
,
Wild type
,
Carcinoma, Non-Small-Cell Lung
,
Disease Progression
,
DNA Mutational Analysis
,
Follow-Up Studies
,
Genetic Association Studies
,
Humans
,
Lung Neoplasms
,
Middle Aged
,
Mutation
,
Neoplasm Staging
,
Predictive Value of Tests
,
Proto-Oncogene Proteins
,
Ras Proteins
,
Survival Analysis
|
Derechos de uso:
|
Cerrado |
Fuente:
|
Lung Cancer. (issn:
0169-5002
)
|
DOI:
|
10.1016/j.lungcan.2010.09.005
|
Editorial:
|
Elsevier
|
Versión del editor:
|
https://dx.doi.org/10.1016/j.lungcan.2010.09.005
|
Código del Proyecto:
|
info:eu-repo/grantAgreement/MSC//RD06%2F0020%2F1024/ES/RED TEMÁTICA DE INVESTIGACIÓN COOPERATIVA DEL CANCER/
|
Agradecimientos:
|
This work was sponsored in part by a grant from the Spanish Society of Medical Oncology (SEOM) and by a grant (RD06/0020/1024) from Red Tematica de Investigacion Cooperativa en Cancer (RTICC), Instituto de Salud Carlos III ...[+]
This work was sponsored in part by a grant from the Spanish Society of Medical Oncology (SEOM) and by a grant (RD06/0020/1024) from Red Tematica de Investigacion Cooperativa en Cancer (RTICC), Instituto de Salud Carlos III (ISCIII), Spanish Ministry of Science and Innovation & European Regional Development Fund (ERDF) "Una manera de hacer Europa". None of the funding agencies were involved in the design, data management, data analysis, manuscript preparation and review, or decision to submit.
[-]
|
Tipo:
|
Artículo
|